Poland· PL-100322640
Sirturo
A bedaquiline product containing bedaquilinum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Bedaquiline is registered in 13 of 19 countries.
Countries holding a registration under ATC J04AK05 (bedaquiline), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Bedaquiline · ATC J04AK05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Bedaquilinum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- J04AK05
- ATC class
- Bedaquiline
- Defined daily dose
- 86 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991140984
- gtin05909991221737
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
325 interactions on record for bedaquiline.
Graded by severity as the source publishes them — 141 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bedaquiline · interactions on record
325 records
- 141 severe
- 182 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Bedaquiline in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSIRTUROJanssen-Cilag International N.V., Beerse
- SpainSIRTURO 100 MG COMPRIMIDOSJanssen-Cilag International N.V
- FinlandSIRTUROJanssen-Cilag International NV
- FranceSIRTURO 100 mg, compriméJANSSEN CILAG INTERNATIONAL NV
- United KingdomSirturo 100mg tabletsJanssen-Cilag Ltd
- IrelandSIRTURO 100 mg tabletsJanssen-Cilag International NV
- IcelandSIRTUROJanssen-Cilag International NV*
- NetherlandsSirturo 100 mg, TabletJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sirturo
- Liechtenstein · Sirturo
- Norway · Sirturo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b5886557-5db7-4d57-979d-7ddfeca8c4d6 GET /v1/drugs/b5886557-5db7-4d57-979d-7ddfeca8c4d6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "100 mg",
"packaging": "05909991140984 ¦ Rpz ¦ EU/1/13/901/001 ¦ 102864\n1 butelka 188 tabl.\n05909991221737 ¦ Rpz ¦ EU/1/13/901/002 ¦ 108392\n24 tabl.",
"substance": "Bedaquilini fumaras 100 mg",
"common_name": "Bedaquilinum",
"pl_product_id": "100322640",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about bedaquiline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.